Navigation Links
Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
Date:11/24/2008

LONDON, Nov. 24 /PRNewswire/ -- The European autoimmune disease diagnostics market has demonstrated sustained growth due to advances in detection technology and automation. Active consolidation is occurring in the market, promoting technology and product integration. However, the lack of clarity with regard to reimbursement policies for autoimmune diagnostic tests persists, posing a challenge to market expansion.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Autoimmune Disease Diagnostics Market, finds that the market earned revenues of $513.5 million in 2008 and estimates this to reach $722.0 million in 2015.

"The development of novel biomarker panels has accelerated the diagnosis of many autoimmune complications," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "Exhaustive R&D by many universities and research organisations has yielded promising results in the use of multiple biomarkers for autoimmune disease diagnosis."

The ability to screen a patient with multiple biomarkers associated with several autoimmune diseases has been shown to improve the accuracy of the diagnosis and has had a significant positive influence on the autoimmune disease diagnostics market. Such novel biomarker panels will continue to offer an added advantage to physicians in the diagnosis of these complications.

Despite the advances in detection technology, the generalised lack of awareness among the public with regard to autoimmune diseases presents a challenge to market growth.

"Such low levels of awareness may derive from the rarity of many autoimmune complications among the general population," explains Ramanathan. "Many patients in Europe, unable to find a proper treatment for their condition, are consequently switching to traditional methods such as oriental medicine."

The need is, therefore, to boost patient awareness. This can be achieved through extensive workshops and disease awareness programmes.

"In conjunction with medical research organisations and hospitals, manufacturers should establish awareness programmes and interactive workshops for the public," advises Ramanathan. "These could highlight the prevalence of autoimmune diseases, while encouraging physicians to interact with the public on the symptoms, etiology and progression of autoimmune diseases."

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European autoimmune disease diagnostics market, then send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

Strategic Analysis of the European Autoimmune Disease Diagnostics Market is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: European POC Connectivity Market, European Immunoassay Diagnostics Market, Western European IVD Markets, and Eastern European IVD Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

   Strategic Analysis of the European Autoimmune Disease Diagnostics Market
                                     M2DC

     Contact:
     Patrick Cairns
     Corporate Communications
     P: +27 18 468 2315
     E: patrick.cairns@frost.com

    http://www.frost.com

'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MDV Expands Team Pursuing Advances in Personalized Medicine
2. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
3. New research field promises radical advances in optical technologies
4. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
5. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
6. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
7. New molecular imaging techniques may lead to advances in disease treatment
8. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
9. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
10. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
11. Human Genome Sciences Advances Oncology Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
Breaking Biology Technology:
(Date:9/3/2020)... ... 2020 , ... Litmus Health , the research-ready infrastructure ... the company’s security practices has been completed. The assessment deemed Litmus infrastructure to ... reviewed Litmus’ processes and systems, assessing them to see whether they adhere to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to ... most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. ... growth of 71 percent. , The Inc. 5000 list represents a unique look ...
Breaking Biology News(10 mins):